Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biogen Idec (NQ: BIIB )

158.71 +0.81 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
48 49 Next >
Looking Into Biogen's Recent Short Interest
Via Benzinga
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Via Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
Via Benzinga
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry
Via Benzinga
BIIB Stock Price Analysis: To Bet Or To Fold The Cards
Massachusetts-based Biogen (BIIB​​​​​​​) is a global biotechnology leader, researching and developing therapies for debilitating diseases impacting the central nervous system. 
Via Talk Markets
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
From Biogen Inc.
Via GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, 
Via Benzinga
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Analyst Ratings for Biogen
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today
Via Benzinga
Is Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy. 
Via The Motley Fool
An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week
Another RSI Buy In a post last month, we wrote about the power of RSI (Relative Strength Index) as a technical indicator (Relative Strength Index) in relation to Stitch Fix, Inc. (NASDAQ: SFIX)  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
From Biogen Inc.
Via GlobeNewswire
3 Struggling Stocks Investors Shouldn't Buy on the Dip
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better. 
Via The Motley Fool
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
The U.S. 
Via Benzinga
7 Low-Volatility Stocks to Buy if You’re a Concerned Investor
With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks. 
Via InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: 
Via Benzinga
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”: 
Via Benzinga
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
From Biogen Inc.
Via GlobeNewswire
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
Biogen Completes Acquisition of Reata Pharmaceuticals
From Biogen Inc.
Via GlobeNewswire
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Benzinga 
Via Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.